IDOi-Pt (IV) prodrug-1

IDOi-Pt (IV) prodrug-1 (Compound 10) is an IDOi-Pt (IV) prodrug. IDOi-Pt (IV) prodrug-1 inhibits IDO expression. IDOi-Pt (IV) prodrug-1 induces apoptosis, decreases the mitochondrial membrane potential, inhibits tumor cell migration and invasion. IDOi-Pt (IV) prodrug-1 induces reactive oxygen species-mediated endoplasmic reticulum stress and secretion of damage-associated molecular patterns (DAMPs), thereby presenting immunogenic cell death (ICD) effects. IDOi-Pt (IV) prodrug-1 has high-efficiency and low-toxicity antitumor effects compared to Cisplatin (HY-17394) [1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Indoleamine 2,3-Dioxygenase (IDO) ; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[NH3][Pt](Cl)(Cl)(O)([NH3])OC(CCCC(N1C2=CC=C(C=C2C(SC3=CC(OC)=CC(OC)=C3)=C1)Cl)=O)=O

Molecular Formula

C21H26Cl3N3O6PtS

Molecular Weight

749.96

References & Citations

[1]Li Z, et al. Novel Indoleamine-2,3-Dioxygenase-Targeted Pt (IV) Prodrugs Regulate the Tumor Immune Microenvironment to Achieve Chemoimmunotherapy In Vitro and In Vivo. J Med Chem. 2025 Feb 27;68 (4) :4352-4372.